Back to the Vioxx case – Kill the drug in time – part 1

The development of a new medical product—particularly in the case of a new medicinal product—costs vast amounts of time and money. Thus it can be costly to terminate a product that is in late stage development or on the market, if the product has already been approved. Product developers will therefore try to keep their products alive.